Cargando…

Correction to: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials

Detalles Bibliográficos
Autores principales:	Ballow, Mark, Wasserman, Richard L., Jolles, Stephen, Chapel, Helen, Berger, Mel, Misbah, Siraj A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028855/ https://www.ncbi.nlm.nih.gov/pubmed/29713933 http://dx.doi.org/10.1007/s10875-018-0504-0

Ejemplares similares

Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
por: Ballow, Mark, et al.
Publicado: (2017)

Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials”
por: Suez, Daniel, et al.
Publicado: (2017)

Ten-year population trends of immunoglobulin use, burden of adult antibody deficiency and feasibility of subcutaneous immunoglobulin (SCIg) replacement in Hong Kong Chinese
por: Kan, Andy Ka Chun, et al.
Publicado: (2022)

Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada
por: Gerth, William C, et al.
Publicado: (2014)

Correction to: Passive blood anaphylaxis: subcutaneous immunoglobulins are a cause of ongoing passive anaphylactic reaction
por: Zdziarski, Przemyslaw, et al.
Publicado: (2018)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
por: Jolles, Stephen
Publicado: (2013)

New Frontiers in Subcutaneous Immunoglobulin Treatment
por: Jolles, Stephen, et al.
Publicado: (2011)

Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy
por: Orange, J S, et al.
Publicado: (2012)

SCIg vs. IVIg: let’s give patients the choice!
por: Samaan, Kathryn K, et al.
Publicado: (2014)

Common infusion-related reactions to subcutaneous immunoglobulin therapy: Managing patient expectations
por: Wasserman, Richard L.
Publicado: (2008)

Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG
por: Anterasian, Christine, et al.
Publicado: (2019)

Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study
por: Keith, Paul K., et al.
Publicado: (2023)

Individualizing Therapy in CIDP: A Mini-Review Comparing the Pharmacokinetics of Ig With SCIg and IVIg
por: Beydoun, Said R., et al.
Publicado: (2021)

SCIG administration: A promising and patient convenient alternative for those receiving long-term IVIG
por: Hassini, Slim, et al.
Publicado: (2022)

Correction to: Adverse drug reactions in older adults: a narrative review of the literature
por: Zazzara, Maria Beatrice, et al.
Publicado: (2021)

Bioavailability of IgG Administered by the Subcutaneous Route
por: Berger, Melvin, et al.
Publicado: (2013)

Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies
por: Mallick, Rajiv, et al.
Publicado: (2018)

Therapeutic Use of Immunoglobulins
por: Stiehm, E. Richard, et al.
Publicado: (2010)

Correction: Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritization
por: King, Charlotte, et al.
Publicado: (2020)

Pediatric subset of primary immunodeficiency patients treated with SCIG: post hoc analysis of SHIFT and IBIS pooled data
por: Moschese, Viviana, et al.
Publicado: (2020)

Correction: Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria
por: Eluwa, George I, et al.
Publicado: (2012)

Adverse Reactions to Intravenous Immunoglobulins - Our Experience
por: Kareva, Lidija, et al.
Publicado: (2018)

Immunodeficient patient experience of emergency switch from intravenous to rapid push subcutaneous immunoglobulin replacement therapy during coronavirus disease 2019 shielding
por: Morgan, Clare, et al.
Publicado: (2022)

Correction: Do Longer Intervals between Challenges Reduce the Risk of Adverse Reactions in Oral Wheat Challenges?
por: Yanagida, Noriyuki, et al.
Publicado: (2015)

Efficacy and Safety of Hizentra(®), a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency
por: Borte, Michael, et al.
Publicado: (2011)

Correction: Fc Receptors for Immunoglobulins and Their Appearance during Vertebrate Evolution
Publicado: (2015)

Correction: Changes in Risk of Immediate Adverse Reactions to Iodinated Contrast Media by Repeated Administrations in Patients with Hepatocellular Carcinoma
Publicado: (2014)

Global immunoglobulin supply: steaming towards the iceberg?
por: Prevot, Johan, et al.
Publicado: (2020)

Correction to: Communicating Adverse Drug Reaction Insights Through Patient Organizations: Experiences from a Pilot Study in the Netherlands
por: Härmark, Linda, et al.
Publicado: (2020)

Correction: The BRCT Domain of PARP-1 Is Required for Immunoglobulin Gene Conversion
por: Paddock, Marcia N., et al.
Publicado: (2018)

Safety and adverse reactions in subcutaneous allergen immunotherapy: a review
por: Incorvaia, Cristoforo, et al.
Publicado: (2023)

Correction to: Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits
por: Askar, Raad, et al.
Publicado: (2021)

Correction: Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study
Publicado: (2023)

Passive blood anaphylaxis: subcutaneous immunoglobulins are a cause of ongoing passive anaphylactic reaction
por: Zdziarski, Przemyslaw, et al.
Publicado: (2017)

Correction to: Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature
por: Onakpoya, Igho J., et al.
Publicado: (2019)

Primary Immune Deficiency: Patients’ Preferences for Replacement Immunoglobulin Therapy
por: Gonzalez, Juan Marcos, et al.
Publicado: (2022)

Use of subcutaneous immunoglobulin in inflammatory myositis
por: Zhou, Alan L, et al.
Publicado: (2021)

Author Correction: Knowledge graph prediction of unknown adverse drug reactions and validation in electronic health records
por: Bean, Daniel M., et al.
Publicado: (2018)

The ocular adverse effects of oral drugs [Correction]
Publicado: (2021)

Correction: Physiological Level Production of Antigen-Specific Human Immunoglobulin in Cloned Transchromosomic Cattle
por: Sano, Akiko, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ti4r7dcad4rke96cb36mohil2p